Edition:
United Kingdom

Livzon Pharmaceutical Group Inc (1513.HK)

1513.HK on Hong Kong Stock

60.85HKD
15 Feb 2018
Change (% chg)

HK$0.45 (+0.75%)
Prev Close
HK$60.40
Open
HK$61.30
Day's High
HK$61.30
Day's Low
HK$60.30
Volume
86,300
Avg. Vol
627,102
52-wk High
HK$69.20
52-wk Low
HK$33.38

Chart for

About

LIVZON PHARMACEUTICAL GROUP INC. is a China based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include western medicine preparation such as gastrointestinal drugs, cardiovascular drugs and antimicrobial drugs and gonadotrophin drugs,... (more)

Overall

Beta: 0.64
Market Cap(Mil.): HK$30,110.53
Shares Outstanding(Mil.): 553.23
Dividend: 0.44
Yield (%): 0.98

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

CORRECTED-BRIEF-Livzon Pharmaceutical Unit's JV Livzon Biologics' Capital Will Be Boosted By 600 Mln Yuan (Feb 7)

* SAYS CAPITAL AT UNIT'S JV LIVZON BIOLOGICS WILL BE BOOSTED BY 600 MILLION YUAN ($94.94 million) Source text in Chinese: http://bit.ly/2nMWH27 Further company coverage: ($1 = 6.3201 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

08 Feb 2018

BRIEF-Livzon Pharmaceutical Group Announces Proposed Cash Dividend Distribution & Share Issue

* ‍RECEIVED NOTICE FROM SHAREHOLDER PROPOSING ISSUE OF 3 BONUS SHARES FOR EVERY 10 SHARES TO ALL SHAREHOLDERS

23 Jan 2018

BRIEF-Livzon Pharmaceutical Group Says Joincare To Sell 49 PCT Equity Interests In Livzon Mab

* PROPOSES TO ENTER AGREEMENT PURSUANT TO WHICH JOINCARE TO SELL 49% EQUITY INTERESTS IN LIVZON MAB FOR RMB294 MILLION Source text for Eikon: Further company coverage:

18 Jan 2018

REFILE-BRIEF-Livzon Pharmaceutical'ss Board Agrees Unit To Invest $30 Mln In Global Health Science Fund II

* SAYS BOARD AGREES UNIT TO INVEST $30 MILLION IN GLOBAL HEALTH SCIENCE FUND II, L.P. Source text in Chinese: http://bit.ly/2CVb0qK Further company coverage: (Reporting by Hong Kong newsroom)

12 Jan 2018

BRIEF-Livzon Pharmaceutical Group receives subsidy of 12.8 mln yuan

* Says it received subsidy of 12.8 million yuan for injection internationalization and development related projects

10 Jan 2018

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says Zhuhai-based biotechnology unit received drug clinical trial approval for drug named Recombinant Human anti-RANKL Monoclonal Antibody Solution for Injection

02 Jan 2018

BRIEF-Livzon Pharmaceutical Co Announces Change In Shareholding Structure Of Livzon MABPharm

* CO & JOINCARE PHARMACEUTICAL INDUSTRY ENTERED FRAMEWORK AGREEMENT RELATING TO CAPITAL CONTRIBUTION TO LIVZON BIOLOGICS

21 Dec 2017

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says its unit received drug clinical trial approval for Recombinant Humanized anti-PD-1 Monoclonal Antibody for Injection

03 Nov 2017

BRIEF-Livzon Pharmaceutical's net profits up in Q3, Jan-Sept

* Says Q3 net profit up 1,719.2 percent y/y at 3.7 billion yuan ($556.85 million), 9-month net profit up 590.7 percent y/y at 4.2 billion yuan

25 Oct 2017

BRIEF-Livzon Pharmaceutical sees FY net profit attributable between RMB4.32 bln - RMB4.48 bln

* Sees FY net profit attributable between RMB4.32 billion - RMB4.48 billion Source text for Eikon: Further company coverage:

25 Oct 2017

Earnings vs. Estimates